Drugs / CAMBRITAXESTAT
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05027568 | Jun → Sep 2021 | — | iOnctura | Completed | No outcome recorded |
| Phase 1/21 trial · 1 met primary | ||||||
| Phase 1/2 | NCT05586516 | Oct 2022 → Aug 2025 | malignant pancreatic neoplasm | iOnctura | Completed | Met primary |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2025-10-14 | iOnctura | Results iOnctura debuts cambritaxestat (IOA-289) clinical data in patients with pancreatic cancer at ESMO ionctura.com ↗
iOnctura, a clinical-stage precision oncology company focused on neglected and hard -to-treat cancers, today announces the Phase Ib study investigating oral autotaxin (ATX) inhibitor, cambritaxestat (IOA-289), has met the primary endpoint: demonstrating safety, tolerability and anti-tumor responses, in combination with standard-of-care chemotherapy, in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC). |
| 2024-03-07 | iOnctura | Regulatory US FDA grants orphan drug designation for iOnctura’s first-in-class autotaxin cancer therapy ionctura.com ↗
iOnctura, a pioneering, clinical-stage biotechnology company developing transformative cancer therapies, today announces that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its autotaxin inhibitor cambritaxestat for the treatment of pancreatic cancer. |
| 2023-10-19 | iOnctura | Results New research highlights potential of iOnctura strategy combining autotaxin and TGF-β inhibitors in cancer ionctura.com ↗
We have uncovered a new mechanism of action for autotaxin in resistance to TGF‐β pathway inhibition. |
| 2023-05-16 | iOnctura | Results Peer-reviewed translational research paves the way for first-in-class autotaxin inhibitor IOA-289 in cancer ionctura.com ↗
iOnctura, a clinical stage biotechnology company developing breakthrough therapies for patients suffering with cancer, today announces the peer-reviewed publication of comprehensive translational research on the novel autotaxin (ATX) inhibitor IOA-2 89 in the ESMO journal Immuno-Oncology and Technology (IOTECH). |
| 2022-04-08 | iOnctura | Results iOnctura data at AACR demonstrates unique mechanism of action for clinical stage autotaxin inhibitor IOA-289 ionctura.com ↗
The AACR presentation demonstrates that by preventing LPA production, IOA-289 has a direct effect on pancreatic cancer cell lines (PDAC cells), inhibiting their growth in vitro. |
All press releases naming this drug 7 releases
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAMBRITAXESTAT | ChEMBL registry synonym — accepted as the source's own label CHEMBL3917975 ↗ |
| Known as | CRT0273750 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3917975 ↗ |
| Known as | IOA-289 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05027568 ↗ |
| Action | Inhibit | “A Study to Assess an ATX Inhibitor (IOA-289) in Healthy Volunteers” NCT05027568 ↗ |
| Modality | Small molecule | — CHEMBL3917975 ↗ |
| Route | Oral | “single ascending oral doses of IOA-289” NCT05027568 ↗ |
| Target | ENPP2 | “Selective Autotaxin (ENPP2) Inhibitor” NCT05586516 ↗ |